Last Week’s Hot Topic On Pulmonary Fibrosis



Last week’s hot topic on pulmonary fibrosis was NY Times Covers Story of IPF Patient’s Progress with Esbriet Treatment written by Isaura Santos.

This article follows a story covered by the NY Times, about an IPF patient’s progress with Esbriet treatment. “I’ve experienced no change in my condition, no major deterioration since I started on Esbriet,” says Daniel Castner in an exclusive interview with The New York Times. “When I was first diagnosed, I started thinking about the last things I’d get to see before I died,” he said in the interview. “Now I don’t think about death.”

Esbriet (pirfenidone), marketed by Roche through its subsidiary Genentech, is an anti-fibrotic drug thought to act by decreasing the production of collagen and growth and inflammatory factors, ultimately leading to a reduction in lung fibrosis.

Read more about pulmonary fibrosis:

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *